<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04509479</url>
  </required_header>
  <id_info>
    <org_study_id>DAC-008-STCCCV</org_study_id>
    <nct_id>NCT04509479</nct_id>
  </id_info>
  <brief_title>National Tunisian Registry of Valvulopathies (NATURE-VALVE)</brief_title>
  <acronym>NATURE-VALVE</acronym>
  <official_title>National Tunisian Registry of Valvulopathies (NATURE-VALVE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dacima Consulting</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Tunisian Society of Cardiology and Cardiovascular Surgery</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Dacima Consulting</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The National Tunisian Registry of Valvulopathies is an observational, prospective and&#xD;
      multicenter study aiming to assess the epidemiological, clinical and therapeutic profile of&#xD;
      valve disease in tunisian departments of cardiology. Cardiologists from both sectors (public&#xD;
      and private) are participating in the study, with 37 investigational centers. Data will be&#xD;
      captured electronically by DACIMA Clinical Suite, according to FDA 21 CFR part 11 (Food and&#xD;
      Drug Administration 21 Code of Federal Regulations part 11), HIPAA (Health Insurance&#xD;
      Portability and Accountability Act) &amp; ICH (International Conference on Harmonisation)&#xD;
      requirements.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 6, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Actual">March 31, 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>6 Months</target_duration>
  <primary_outcome>
    <measure>Valvulopathies incidence</measure>
    <time_frame>at inclusion</time_frame>
    <description>Number of subjects with valvular disease (mitral or aortic or tricuspid) and willing to participate at the study</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Major adverse cardiovascular events (MACE)</measure>
    <time_frame>at 6 months of follow-up</time_frame>
    <description>Number of patients with Major adverse cardiovascular events (MACE), including nonfatal stroke, nonfatal myocardial infarction, and cardiovascular death.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Valvular Heart Disease</condition>
  <condition>Valvular Stenosis</condition>
  <condition>Valvular Insufficiency</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Valve replacement</intervention_name>
    <description>Description of valve replacements</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with valvular disease&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients originated from Tunisia&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
          -  Patients with at least one of the following conditions :&#xD;
&#xD;
               1. moderate to severe native mitral and / or aortic and / or tricuspid native valve&#xD;
                  disease&#xD;
&#xD;
               2. and / or a history of a previous percutaneous or surgical valve intervention&#xD;
&#xD;
               3. and / or a history of infectious endocarditis&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Congenital valve diseases not including bicuspid aortic valve&#xD;
&#xD;
          -  Isolated pulmonary valvulopathies&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fathia Mghaieth, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Tunisian Society of Cardiology and Cardiovascular Surgery</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lilia Zakhama, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Tunisian Society of Cardiology and Cardiovascular Surgery</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Leila Abid, MD</last_name>
    <phone>+21698230250</phone>
    <email>leilaabidt@yahoo.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rabie Razgallah, MD</last_name>
    <phone>+21620509729</phone>
    <email>r.razgallah@dacimasoftware.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Tunisian Society of Cardiology and CardioVascular Surgery</name>
      <address>
        <city>Tunis</city>
        <zip>1053</zip>
        <country>Tunisia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leila ABID, MD</last_name>
      <phone>+21698230250</phone>
      <email>leilaabidt@yahoo.fr</email>
    </contact>
    <contact_backup>
      <last_name>Rabie Razgallah, MD</last_name>
      <phone>+21620509729</phone>
      <email>r.razgallah@dacimasoftware.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Tunisia</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>August 9, 2020</study_first_submitted>
  <study_first_submitted_qc>August 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 12, 2020</study_first_posted>
  <last_update_submitted>April 16, 2021</last_update_submitted>
  <last_update_submitted_qc>April 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Valvular</keyword>
  <keyword>Heart</keyword>
  <keyword>Aortic</keyword>
  <keyword>Mitral</keyword>
  <keyword>Tricuspid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Heart Valve Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

